Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
ADMET for Medicinal Chemists [[electronic resource] ] : A Practical Guide
| ADMET for Medicinal Chemists [[electronic resource] ] : A Practical Guide |
| Autore | Tsaioun Katya |
| Pubbl/distr/stampa | Hoboken, : Wiley, 2012 |
| Descrizione fisica | 1 online resource (524 p.) |
| Disciplina |
615.19
615/.19 |
| Altri autori (Persone) | KatesSteven A |
| Soggetto topico |
Drug Design
Drug Toxicity Drugs - Testing Drugs --Testing --Juvenile literature Pharmaceutical Preparations - chemistry Pharmacokinetics Metabolic Phenomena Drug Discovery Pharmacological Phenomena Natural Science Disciplines Kinetics Chemicals and Drugs Poisoning Biochemical Phenomena Chemistry, Pharmaceutical Substance-Related Disorders Disciplines and Occupations Investigative Techniques Physiological Phenomena Phenomena and Processes Chemical Phenomena Diseases Pharmacology Analytical, Diagnostic and Therapeutic Techniques and Equipment Biological Science Disciplines Chemistry Pharmaceutical Preparations Health & Biological Sciences Pharmacy, Therapeutics, & Pharmacology |
| ISBN |
1-280-59122-6
9786613621054 0-470-91509-9 0-470-91511-0 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
ADMET for Medicinal Chemists: A Practical Guide; CONTENTS; Preface; Contributors; 1 Introduction; 1.1 Introduction; 1.2 Voyage Through The Digestive System; 1.2.1 The Mouth; 1.2.2 The Stomach; 1.2.3 The Small Intestine: Duodenum; 1.2.4 The Small and Large Intestine: Jejunum, Ileum, Colon; 1.2.5 Hepatic-Portal Vein; 1.3 The Liver Metabolism; 1.3.1 CYP450 (CYPs); 1.4 The Kidneys; 1.4.1 Active Tubular Secretion; 1.4.2 Passive Tubular Reabsorption; 1.5 Conclusions; References; 2 In Silico ADME/Tox Predictions; 2.1 Introduction; 2.2 Key Computer Methods for ADME/Tox Predictions
2.2.1 Drug Discovery2.2.2 Applying or Not ADME/Tox Predictions, Divided Opinions; 2.2.3 In Silico ADME/Tox Methods and Modeling Approaches; 2.2.4 Physicochemistry, Pharmacokinetics, Drug-Like and Lead-Like Concepts; 2.2.5 Lipophilicity; 2.2.6 pKa; 2.2.7 Transport Proteins; 2.2.8 Plasma Protein Binding; 2.2.9 Metabolism; 2.2.10 Elimination; 2.2.11 Toxicity; 2.3 Preparation of Compound Collections and Computer Programs, Challenging ADME/Tox Predictions and Statistical Methods; 2.3.1 Preparation of Compound Collections and Computer Programs 2.3.2 Preparing a Compound Collection: Materials and Methods2.3.3 Cleaning and Designing the Compound Collection; 2.3.4 Searching for Similarity; 2.3.5 Generating 3D Structures; 2.4 ADME/Tox Predictions within Pharmaceutics Companies; 2.4.1 Actelion Pharmaceuticals Ltd.; 2.4.2 Bayer; 2.4.3 Bristol-Myers Squibb; 2.4.4 Hoffmann-La Roche Ltd.; 2.4.5 Neurogen Corporation; 2.4.6 Novartis; 2.4.7 Schering AG; 2.4.8 Vertex Pharmaceuticals; 2.5 Challenging ADME/Tox Predictions; 2.5.1 Tolcapone; 2.5.2 Factor V Inhibitors; 2.5.3 CRF-1 Receptor Antagonists; 2.6 Statistical Methods 2.6.1 Principal Component Analysis2.6.2 Partial Least Square; 2.6.3 Support Vector Machine; 2.6.4 Decision Trees; 2.6.5 Neural Networks; 2.7 Conclusions; References; 3 Absorption and Physicochemical Properties of the NCE; 3.1. Introduction; 3.2. Physicochemical Properties; 3.3. Stability; 3.4. Dissolution and Solubility; 3.4.1. Dissolution Rate, Particle Size, and Solubility; 3.4.2. pH and Salts; 3.4.3. In Vivo Solubilization; 3.5. Solid State; References; 4 ADME; 4.1 Introduction; 4.2 Absorption; 4.2.1 Route of Administration; 4.2.2 Factors Determining Oral Bioavailability; 4.3 Distribution 4.3.1 Drug Distribution4.3.2 Volume of Distribution; 4.3.3 Free Drug Concentration; 4.3.4 CNS Penetration; 4.4 Elimination; 4.4.1 Elimination Versus Clearance; 4.4.2 Metabolism Versus Excretion; 4.4.3 Drug-Free Fraction and Clearance; 4.4.4 Lipophilicity and Clearance; 4.4.5 Transporters and Clearance; 4.4.6 Metabolism; 4.4.7 Excretion; 4.5 Drug Interactions; 4.5.1 Absorption-Driven DDI; 4.5.2 Distribution-Driven DDI; 4.5.3 Excretion-Driven DDI; 4.5.4 Metabolism-Driven DDI; 4.5.5 Tools for Studying Drug Metabolism; 4.5.6 Applications of Drug Metabolism Tools 4.5.7 Tools for Studying Drug Excretion |
| Record Nr. | UNINA-9910133588303321 |
Tsaioun Katya
|
||
| Hoboken, : Wiley, 2012 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
ADMET for Medicinal Chemists [[electronic resource] ] : A Practical Guide
| ADMET for Medicinal Chemists [[electronic resource] ] : A Practical Guide |
| Autore | Tsaioun Katya |
| Pubbl/distr/stampa | Hoboken, : Wiley, 2012 |
| Descrizione fisica | 1 online resource (524 p.) |
| Disciplina |
615.19
615/.19 |
| Altri autori (Persone) | KatesSteven A |
| Soggetto topico |
Drug Design
Drug Toxicity Drugs - Testing Drugs --Testing --Juvenile literature Pharmaceutical Preparations - chemistry Pharmacokinetics Metabolic Phenomena Drug Discovery Pharmacological Phenomena Natural Science Disciplines Kinetics Chemicals and Drugs Poisoning Biochemical Phenomena Chemistry, Pharmaceutical Substance-Related Disorders Disciplines and Occupations Investigative Techniques Physiological Phenomena Phenomena and Processes Chemical Phenomena Diseases Pharmacology Analytical, Diagnostic and Therapeutic Techniques and Equipment Biological Science Disciplines Chemistry Pharmaceutical Preparations Health & Biological Sciences Pharmacy, Therapeutics, & Pharmacology |
| ISBN |
1-280-59122-6
9786613621054 0-470-91509-9 0-470-91511-0 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
ADMET for Medicinal Chemists: A Practical Guide; CONTENTS; Preface; Contributors; 1 Introduction; 1.1 Introduction; 1.2 Voyage Through The Digestive System; 1.2.1 The Mouth; 1.2.2 The Stomach; 1.2.3 The Small Intestine: Duodenum; 1.2.4 The Small and Large Intestine: Jejunum, Ileum, Colon; 1.2.5 Hepatic-Portal Vein; 1.3 The Liver Metabolism; 1.3.1 CYP450 (CYPs); 1.4 The Kidneys; 1.4.1 Active Tubular Secretion; 1.4.2 Passive Tubular Reabsorption; 1.5 Conclusions; References; 2 In Silico ADME/Tox Predictions; 2.1 Introduction; 2.2 Key Computer Methods for ADME/Tox Predictions
2.2.1 Drug Discovery2.2.2 Applying or Not ADME/Tox Predictions, Divided Opinions; 2.2.3 In Silico ADME/Tox Methods and Modeling Approaches; 2.2.4 Physicochemistry, Pharmacokinetics, Drug-Like and Lead-Like Concepts; 2.2.5 Lipophilicity; 2.2.6 pKa; 2.2.7 Transport Proteins; 2.2.8 Plasma Protein Binding; 2.2.9 Metabolism; 2.2.10 Elimination; 2.2.11 Toxicity; 2.3 Preparation of Compound Collections and Computer Programs, Challenging ADME/Tox Predictions and Statistical Methods; 2.3.1 Preparation of Compound Collections and Computer Programs 2.3.2 Preparing a Compound Collection: Materials and Methods2.3.3 Cleaning and Designing the Compound Collection; 2.3.4 Searching for Similarity; 2.3.5 Generating 3D Structures; 2.4 ADME/Tox Predictions within Pharmaceutics Companies; 2.4.1 Actelion Pharmaceuticals Ltd.; 2.4.2 Bayer; 2.4.3 Bristol-Myers Squibb; 2.4.4 Hoffmann-La Roche Ltd.; 2.4.5 Neurogen Corporation; 2.4.6 Novartis; 2.4.7 Schering AG; 2.4.8 Vertex Pharmaceuticals; 2.5 Challenging ADME/Tox Predictions; 2.5.1 Tolcapone; 2.5.2 Factor V Inhibitors; 2.5.3 CRF-1 Receptor Antagonists; 2.6 Statistical Methods 2.6.1 Principal Component Analysis2.6.2 Partial Least Square; 2.6.3 Support Vector Machine; 2.6.4 Decision Trees; 2.6.5 Neural Networks; 2.7 Conclusions; References; 3 Absorption and Physicochemical Properties of the NCE; 3.1. Introduction; 3.2. Physicochemical Properties; 3.3. Stability; 3.4. Dissolution and Solubility; 3.4.1. Dissolution Rate, Particle Size, and Solubility; 3.4.2. pH and Salts; 3.4.3. In Vivo Solubilization; 3.5. Solid State; References; 4 ADME; 4.1 Introduction; 4.2 Absorption; 4.2.1 Route of Administration; 4.2.2 Factors Determining Oral Bioavailability; 4.3 Distribution 4.3.1 Drug Distribution4.3.2 Volume of Distribution; 4.3.3 Free Drug Concentration; 4.3.4 CNS Penetration; 4.4 Elimination; 4.4.1 Elimination Versus Clearance; 4.4.2 Metabolism Versus Excretion; 4.4.3 Drug-Free Fraction and Clearance; 4.4.4 Lipophilicity and Clearance; 4.4.5 Transporters and Clearance; 4.4.6 Metabolism; 4.4.7 Excretion; 4.5 Drug Interactions; 4.5.1 Absorption-Driven DDI; 4.5.2 Distribution-Driven DDI; 4.5.3 Excretion-Driven DDI; 4.5.4 Metabolism-Driven DDI; 4.5.5 Tools for Studying Drug Metabolism; 4.5.6 Applications of Drug Metabolism Tools 4.5.7 Tools for Studying Drug Excretion |
| Record Nr. | UNINA-9910830164603321 |
|
Tsaioun Katya
|
||
| Hoboken, : Wiley, 2012 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Analgesics : from chemistry and pharmacology to clinical application
| Analgesics : from chemistry and pharmacology to clinical application |
| Pubbl/distr/stampa | [Place of publication not identified], : Wiley VCH, 2002 |
| Descrizione fisica | 1 online resource (604 pages) |
| Disciplina | 615/.783 |
| Soggetto topico |
Analgesics
Central Nervous System Agents Sensory System Agents Peripheral Nervous System Agents Therapeutic Uses Pharmacologic Actions Physiological Effects of Drugs Chemical Actions and Uses Chemicals and Drugs Health & Biological Sciences Pharmacy, Therapeutics, & Pharmacology |
| Soggetto genere / forma | Electronic books. |
| ISBN |
1-280-64448-6
9786610644483 3-527-60561-4 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910144275603321 |
| [Place of publication not identified], : Wiley VCH, 2002 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Analgesics : from chemistry and pharmacology to clinical application
| Analgesics : from chemistry and pharmacology to clinical application |
| Pubbl/distr/stampa | [Place of publication not identified], : Wiley VCH, 2002 |
| Descrizione fisica | 1 online resource (604 pages) |
| Disciplina | 615/.783 |
| Soggetto topico |
Analgesics
Central Nervous System Agents Sensory System Agents Peripheral Nervous System Agents Therapeutic Uses Pharmacologic Actions Physiological Effects of Drugs Chemical Actions and Uses Chemicals and Drugs Health & Biological Sciences Pharmacy, Therapeutics, & Pharmacology |
| ISBN |
1-280-64448-6
9786610644483 3-527-60561-4 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910830272603321 |
| [Place of publication not identified], : Wiley VCH, 2002 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Analgesics : from chemistry and pharmacology to clinical application
| Analgesics : from chemistry and pharmacology to clinical application |
| Pubbl/distr/stampa | [Place of publication not identified], : Wiley VCH, 2002 |
| Descrizione fisica | 1 online resource (604 pages) |
| Disciplina | 615/.783 |
| Soggetto topico |
Analgesics
Central Nervous System Agents Sensory System Agents Peripheral Nervous System Agents Therapeutic Uses Pharmacologic Actions Physiological Effects of Drugs Chemical Actions and Uses Chemicals and Drugs Health & Biological Sciences Pharmacy, Therapeutics, & Pharmacology |
| ISBN |
1-280-64448-6
9786610644483 3-527-60561-4 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910876621103321 |
| [Place of publication not identified], : Wiley VCH, 2002 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Antiviral Drugs [[electronic resource] ] : From Basic Discovery Through Clinical Trials
| Antiviral Drugs [[electronic resource] ] : From Basic Discovery Through Clinical Trials |
| Autore | Kazmierski Wieslaw M |
| Pubbl/distr/stampa | Hoboken, : Wiley, 2011 |
| Descrizione fisica | 1 online resource (470 p.) |
| Disciplina | 615/.7924 |
| Soggetto topico |
Antiviral Agents -- therapeutic use
Antiviral agents Clinical Trials as Topic Drug Discovery Drug Evaluation Epidemiologic Studies Chemistry, Pharmaceutical Evaluation Studies as Topic Investigative Techniques Anti-Infective Agents Epidemiologic Methods Pharmacology Therapeutic Uses Health Care Evaluation Mechanisms Chemistry Biological Science Disciplines Natural Science Disciplines Quality of Health Care Public Health Pharmacologic Actions Environment and Public Health Health Care Quality, Access, and Evaluation Chemical Actions and Uses Health Care Antiviral Agents Health & Biological Sciences Pharmacy, Therapeutics, & Pharmacology |
| ISBN |
1-283-20363-4
9786613203632 0-470-92935-9 0-470-92934-0 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
ANTIVIRAL DRUGS; CONTENTS; CONTRIBUTORS; PREFACE; PART I HUMAN IMMUNODEFICIENCY VIRUS; 1 Discovery and Development of Atazanavir; 2 Discovery and Development of PL-100, A Novel HIV-1 Protease Inhibitor; 3 Darunavir (Prezista, TMC114): From Bench to Clinic, Improving Treatment Options for HIV-Infected Patients; 4 Discovery and Development of Tipranavir; 5 TMC278 (Rilpivirine): A Next-Generation NNRTI in Phase III Clinical Development for Treatment-Naive Patients; 6 Etravirine: From TMC125 to Intelence: A Treatment Paradigm Shift for HIV-Infected Patients
7 Discovery and Development of Tenofovir Disoproxil Fumarate8 Discovery and Development of Apricitabine; 9 Discovery and Development of Maraviroc and PF-232798: CCR5 Antagonists for the Treatment of HIV-1 Infection; 10 Discovery of the CCR5 Antagonist Vicriviroc (Sch 417690/Sch-D) for the Treatment of HIV-1 Infection; 11 Discovery and Development of HIV-1 Entry Inhibitors That Target gp120; 12 Discovery of MK-0536: A Potential Second-Generation HIV-1 Integrase Strand Transfer Inhibitor with a High Genetic Barrier to Mutation; 13 Discovery and Development of HIV Integrase Inhibitor Raltegravir 14 Elvitegravir: A Novel Monoketo Acid HIV-1 Integrase Strand Transfer InhibitorPART II HEPATITIS C VIRUS; 15 Discovery and Development of Telaprevir; 16 Discovery and Development of BILN 2061 and Follow-up BI 201335; 17 Intervention of Hepatitis C Replication Through NS3-4A, the Protease Inhibitor Boceprevir; 18 Discovery and Development of the HCV NS3/4A Protease Inhibitor Danoprevir (ITMN-191/RG7227); 19 Discovery and Development of the HCV Protease Inhibitor TMC435; 20 Discovery and Clinical Evaluation of the Nucleoside Analog Balapiravir (R1626) for the Treatment of HCV Infection 21 Discovery and Development of PSI-6130/RG712822 Discovery of Cyclophilin Inhibitor NIM811 as a Novel Therapeutic Agent for HCV; 23 HCV Viral Entry Inhibitors; PART III RESPIRATORY SYNCYTIAL VIRUS INHIBITORS; 24 Discovery of the RSV Inhibitor TMC353121; 25 Discovery and Development of Orally Active RSV Fusion Inhibitors; 26 Discovery and Development of RSV604; PART IV INFLUENZA, HEPATITIS B, AND CYTOMEGALOVIRUS INHIBITORS; 27 Discovery and Development of Influenza Virus Sialidase Inhibitor Relenza; 28 Discovery and Development of Entecavir 29 Benzimidazole Ribonucleosides: Novel Drug Candidates for the Prevention and Treatment of Cytomegalovirus DiseasesINDEX; Color Plate |
| Record Nr. | UNINA-9910139613803321 |
|
Kazmierski Wieslaw M
|
||
| Hoboken, : Wiley, 2011 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Antiviral Drugs [[electronic resource] ] : From Basic Discovery Through Clinical Trials
| Antiviral Drugs [[electronic resource] ] : From Basic Discovery Through Clinical Trials |
| Autore | Kazmierski Wieslaw M |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Hoboken, : Wiley, 2011 |
| Descrizione fisica | 1 online resource (470 p.) |
| Disciplina | 615/.7924 |
| Soggetto topico |
Antiviral Agents -- therapeutic use
Antiviral agents Clinical Trials as Topic Drug Discovery Drug Evaluation Epidemiologic Studies Chemistry, Pharmaceutical Evaluation Studies as Topic Investigative Techniques Anti-Infective Agents Epidemiologic Methods Pharmacology Therapeutic Uses Health Care Evaluation Mechanisms Chemistry Biological Science Disciplines Natural Science Disciplines Quality of Health Care Public Health Pharmacologic Actions Environment and Public Health Health Care Quality, Access, and Evaluation Chemical Actions and Uses Delivery of Health Care Antiviral Agents Health & Biological Sciences Pharmacy, Therapeutics, & Pharmacology |
| ISBN |
1-283-20363-4
9786613203632 0-470-92935-9 0-470-92934-0 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
ANTIVIRAL DRUGS; CONTENTS; CONTRIBUTORS; PREFACE; PART I HUMAN IMMUNODEFICIENCY VIRUS; 1 Discovery and Development of Atazanavir; 2 Discovery and Development of PL-100, A Novel HIV-1 Protease Inhibitor; 3 Darunavir (Prezista, TMC114): From Bench to Clinic, Improving Treatment Options for HIV-Infected Patients; 4 Discovery and Development of Tipranavir; 5 TMC278 (Rilpivirine): A Next-Generation NNRTI in Phase III Clinical Development for Treatment-Naive Patients; 6 Etravirine: From TMC125 to Intelence: A Treatment Paradigm Shift for HIV-Infected Patients
7 Discovery and Development of Tenofovir Disoproxil Fumarate8 Discovery and Development of Apricitabine; 9 Discovery and Development of Maraviroc and PF-232798: CCR5 Antagonists for the Treatment of HIV-1 Infection; 10 Discovery of the CCR5 Antagonist Vicriviroc (Sch 417690/Sch-D) for the Treatment of HIV-1 Infection; 11 Discovery and Development of HIV-1 Entry Inhibitors That Target gp120; 12 Discovery of MK-0536: A Potential Second-Generation HIV-1 Integrase Strand Transfer Inhibitor with a High Genetic Barrier to Mutation; 13 Discovery and Development of HIV Integrase Inhibitor Raltegravir 14 Elvitegravir: A Novel Monoketo Acid HIV-1 Integrase Strand Transfer InhibitorPART II HEPATITIS C VIRUS; 15 Discovery and Development of Telaprevir; 16 Discovery and Development of BILN 2061 and Follow-up BI 201335; 17 Intervention of Hepatitis C Replication Through NS3-4A, the Protease Inhibitor Boceprevir; 18 Discovery and Development of the HCV NS3/4A Protease Inhibitor Danoprevir (ITMN-191/RG7227); 19 Discovery and Development of the HCV Protease Inhibitor TMC435; 20 Discovery and Clinical Evaluation of the Nucleoside Analog Balapiravir (R1626) for the Treatment of HCV Infection 21 Discovery and Development of PSI-6130/RG712822 Discovery of Cyclophilin Inhibitor NIM811 as a Novel Therapeutic Agent for HCV; 23 HCV Viral Entry Inhibitors; PART III RESPIRATORY SYNCYTIAL VIRUS INHIBITORS; 24 Discovery of the RSV Inhibitor TMC353121; 25 Discovery and Development of Orally Active RSV Fusion Inhibitors; 26 Discovery and Development of RSV604; PART IV INFLUENZA, HEPATITIS B, AND CYTOMEGALOVIRUS INHIBITORS; 27 Discovery and Development of Influenza Virus Sialidase Inhibitor Relenza; 28 Discovery and Development of Entecavir 29 Benzimidazole Ribonucleosides: Novel Drug Candidates for the Prevention and Treatment of Cytomegalovirus DiseasesINDEX; Color Plate |
| Record Nr. | UNINA-9910808713803321 |
|
Kazmierski Wieslaw M
|
||
| Hoboken, : Wiley, 2011 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Botanical Medicine in Clinical Practice [[electronic resource]]
| Botanical Medicine in Clinical Practice [[electronic resource]] |
| Autore | Watson R.R |
| Pubbl/distr/stampa | CABI, 2008 |
| Descrizione fisica | 1 online resource (937 p.) |
| Disciplina | 615.321 |
| Altri autori (Persone) | PreedyV.R |
| Soggetto topico |
Botany, Medical
Herbs -- Therapeutic use Phytotherapy Plant preparations Plants, Medicinal Herbs - Therapeutic use Materia medica, Vegetable Biological Products Plants Complementary Therapies Therapeutics Eukaryota Complex Mixtures Analytical, Diagnostic and Therapeutic Techniques and Equipment Organisms Chemicals and Drugs Plant Preparations Health & Biological Sciences Pharmacy, Therapeutics, & Pharmacology |
| ISBN | 1-84593-730-9 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Contents; Contributors; Acknowledgements; Introduction; I. Herbal Remedies with Geographic Historic Uses; 1. African Plants as Antipathogen Agents: Efficacy and Clinical Evidence; 2. African Medicinal Plants for the Treatment of HIV/AIDS; 3. African Plants and Herbs in Asthma Therapy; 4. Arab Herbal Medicine; 5. Bolivian Plant Extracts: Traditional Medicine; 6. Brazilian Medicinal Plants in Gastrointestinal Therapy; 7. Chinese Herbal Medicine in Asthma and Allergy Treatment; 8. Plant Drugs and Extracts in Human and Veterinary Health Promotion within Europe: Benefits and Risks
9. Himalayan Mayapple: Traditional Uses, Clinical Indications and Future Prospects10. Neem Leaves: Indian Herbal Medicine; 11. Japanese Botanical Medicines in Liver and Gastrointestinal Health: Risk and Benefits; 12. Japanese Herbal Medicine in Western-style Modern Medical System; 13. Korean Traditional Herbal Materials and Herbal Formulas in Health Promotion: Benefits and Safety; 14. South American Plants in Folk Medicine: Chilean and Patagonian Cases; 15. The Use of Herbal Medicines by Mexican Americans in the USA: Risk/Benefits?; II. Infectious Disease Treatment and Immunomodulation 16. Antibacterial Effects of Tannins in Children and Adults17. Antimicrobial Activity of Medicinal Plants from South America; 18. Plant Oils and Anti-pathogen Immune Stimulation; 19. Novel Anti-schistosomal Drugs from Medical Plants; 20. Caribbean Plant Therapies to Treat Diseases; 21. Essential Oils Inhibit Replication of Herpes Simplex Virus Type 1 and Type 2; 22. Japanese Vegetable Juice, Aojiru as Immunomodulators; 23. Micronutrients and Nutrient Synergy in Immunodeficiency and Infectious Disease; 24. Botanicals in Infectious Disease Treatment; 25. Herbs and Infectious Disease 26. Health Promotion in Relation to Respiratory Viral InfectionsIII. Treatment of Disorders; i. Cancer Prevention and Treatment; 27. Black Cohosh Extracts and Cancer; 28. Botanicals for Benign Prostatic Hyperplasia; 29. Brazilian Anticancer Botanical Agents; 30. Cruciferous Vegetables and Bladder Cancer; 31. Mushrooms and the Prevention and Treatment of Cancer; 32. Mushroom Secondary Metabolites and Cancer; 33. Ginger and Curcumin in Cancer Prevention and Health Promotion; 34. Bioavailability and Cancer Preventive Activity of Green Tea Polyphenols 35. Herbal Ingredients for the Inhibition of Tumour-induced Angiogenesis36. Herbal Products in Dermatology: Implications for Photoaging, Skin Cancer Prevention and the Treatment of Cutaneous Disease; 37. Lichen Extracts and Cancer; 38. Magic Fusion: the Meaning of Integration in Medicine; 39. Dietary Phytochemicals in Prevention and Therapy of Cancer; 40. Phytochemicals and Anticancer Mechanisms; 41. Plant Extracts and Breast Cancer; 42. Plant Polyphenols and Phyto-oestrogens in Cancer Prevention; 43. Russian Medicinal Plants in Treatment of Cancer 44. Scutellaria: Potential Use in Cancer Prevention and Treatment |
| Record Nr. | UNINA-9910446322703321 |
|
Watson R.R
|
||
| CABI, 2008 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Characterization of impurities and degradants using mass spectrometry / / edited by Birendra N. Pramanik, Mike S. Lee, Guodong Chen
| Characterization of impurities and degradants using mass spectrometry / / edited by Birendra N. Pramanik, Mike S. Lee, Guodong Chen |
| Pubbl/distr/stampa | Hoboken : , : Wiley, , 2011 |
| Descrizione fisica | 1 online resource (xxii, 462 pages) : illustrations |
| Disciplina |
615.1
615/.1 |
| Altri autori (Persone) |
PramanikBirendra N. <1944->
LeeMike S. <1960-> ChenGuodong |
| Collana | Wiley Series on Pharmaceutical Science and Biotechnology: Practices, Applications and Methods |
| Soggetto topico |
Drugs - Analysis
Drugs - Spectra Mass spectrometry Contamination (Technology) Public Health Chemistry Techniques, Analytical Investigative Techniques Environment and Public Health Health Care Pharmaceutical Preparations Mass Spectrometry Drug Contamination Health & Biological Sciences Pharmacy, Therapeutics, & Pharmacology |
| ISBN |
1-283-23943-4
9786613239433 0-470-92136-6 0-470-92137-4 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
CHARACTERIZATION OF IMPURITIES AND DEGRADANTS USING MASS SPECTROMETRY; CONTENTS; PREFACE; CONTRIBUTORS; ACRONYMS; PART I: METHODOLOGY; 1. Introduction to Mass Spectrometry; 1.1. History; 1.1.1. Atomic Physics; 1.1.2. Early Applications; 1.1.3. Organic Structural Analysis; 1.1.4. The Biological Mass Spectrometry Revolution; 1.2. Ionization Methods; 1.3. Mass Spectrometer Types; 1.3.1. Magnetic Sector Mass Spectrometers; 1.3.2. Quadrupole Mass Filter and Quadrupole Ion Trap Mass Spectrometers; 1.3.3. Time-of-Flight Mass Spectrometers
1.3.4. Fourier Transform Ion Cyclotron Resonance Mass Spectrometers; 1.3.5. Orbitrap Mass Spectrometers; 1.4. Tandem Mass Spectrometry; 1.4.1. Ion Isolation; 1.4.2. Ion-Molecule Collisions and Collision-Induced Dissociation; 1.4.3. Electron Capture Dissociation and Electron Transfer Dissociation; 1.5. Separation Techniques Coupled to Mass Spectrometry; 1.5.1. Gas Chromatography-Mass Spectrometry; 1.5.2. Liquid Chromatography-Mass Spectrometry; 1.5.3. Capillary Electrophoresis-Mass Spectrometry; 1.5.4. Ion Mobility Spectrometry-Mass Spectrometry; 1.6. Prospects for Mass Spectrometry; References 2. LC Method Development and Strategies; 2.1. Introduction; 2.2. Column, pH, and Solvent Screening; 2.2.1. Resolution: Goal of Separation; 2.2.2. Screening: Systematic Approach to Seeking Selectivity; 2.2.3. Screening Instrumentation and Controlling Software; 2.3. Gradient and Temperature Optimization; 2.4. Orthogonal Screening; 2.4.1. Method Orthogonality; 2.4.2. Selection of Orthogonal Methods; 2.4.3. Impurity Orthogonal Screening; 2.5. High-Efficiency Separation; 2.6. Conclusions; References 3. Rapid Analysis of Drug-Related Substances using Desorption Electrospray Ionization and Direct Analysis in Real Time Ionization Mass Spectrometry; 3.1. Introduction; 3.2. Ionization Apparatus, Mechanisms, and General Performance; 3.2.1. Desorption Electrospray Ionization (DESI); 3.2.2. Direct Analysis in Real Time (DART); 3.3. Drug Analysis in Biological Matrices using DESI and DART; 3.3.1. DESI Application; 3.3.2. DART Application; 3.4. High-Throughput Analysis; 3.5. Chemical Imaging and Profiling; 3.6. Future Perspectives; References; 4. Orbitrap High-Resolution Applications 4.1. Historical Anecdote; 4.2. General Description of Orbitrap Operating Principles; 4.3. The Orbitrap is a "Fourier Transform" Device; 4.4. Performing Experiments in Trapping Devices; 4.4.1. "Raw" HPLC Data Look Like Infusion Data; 4.4.2. How Much Mass Resolution Should Be Used During HPLC; 4.5. Determining Elemental Compositions of "Unknowns" Using an Orbitrap; 4.6. Orbitrap Figures of Merit in Mass Measurement; 4.6.1. Accuracy; 4.6.2. Precision; 4.6.3. Discussion; 4.7. HPLC Orbitrap MS: Accurate Mass Demonstration and Differentiation of Small Molecule Formulas Very Proximate in Mass/Charge Ratio Space |
| Record Nr. | UNINA-9910132377503321 |
| Hoboken : , : Wiley, , 2011 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Characterization of impurities and degradants using mass spectrometry / / edited by Birendra N. Pramanik, Mike S. Lee, Guodong Chen
| Characterization of impurities and degradants using mass spectrometry / / edited by Birendra N. Pramanik, Mike S. Lee, Guodong Chen |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Hoboken : , : Wiley, , 2011 |
| Descrizione fisica | 1 online resource (xxii, 462 pages) : illustrations |
| Disciplina |
615.1
615/.1 |
| Altri autori (Persone) |
PramanikBirendra N. <1944->
LeeMike S. <1960-> ChenGuodong |
| Collana | Wiley Series on Pharmaceutical Science and Biotechnology: Practices, Applications and Methods |
| Soggetto topico |
Drugs - Analysis
Drugs - Spectra Mass spectrometry Contamination (Technology) Public Health Chemistry Techniques, Analytical Investigative Techniques Environment and Public Health Delivery of Health Care Pharmaceutical Preparations Mass Spectrometry Drug Contamination Health & Biological Sciences Pharmacy, Therapeutics, & Pharmacology |
| ISBN |
1-283-23943-4
9786613239433 0-470-92136-6 0-470-92137-4 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
CHARACTERIZATION OF IMPURITIES AND DEGRADANTS USING MASS SPECTROMETRY; CONTENTS; PREFACE; CONTRIBUTORS; ACRONYMS; PART I: METHODOLOGY; 1. Introduction to Mass Spectrometry; 1.1. History; 1.1.1. Atomic Physics; 1.1.2. Early Applications; 1.1.3. Organic Structural Analysis; 1.1.4. The Biological Mass Spectrometry Revolution; 1.2. Ionization Methods; 1.3. Mass Spectrometer Types; 1.3.1. Magnetic Sector Mass Spectrometers; 1.3.2. Quadrupole Mass Filter and Quadrupole Ion Trap Mass Spectrometers; 1.3.3. Time-of-Flight Mass Spectrometers
1.3.4. Fourier Transform Ion Cyclotron Resonance Mass Spectrometers; 1.3.5. Orbitrap Mass Spectrometers; 1.4. Tandem Mass Spectrometry; 1.4.1. Ion Isolation; 1.4.2. Ion-Molecule Collisions and Collision-Induced Dissociation; 1.4.3. Electron Capture Dissociation and Electron Transfer Dissociation; 1.5. Separation Techniques Coupled to Mass Spectrometry; 1.5.1. Gas Chromatography-Mass Spectrometry; 1.5.2. Liquid Chromatography-Mass Spectrometry; 1.5.3. Capillary Electrophoresis-Mass Spectrometry; 1.5.4. Ion Mobility Spectrometry-Mass Spectrometry; 1.6. Prospects for Mass Spectrometry; References 2. LC Method Development and Strategies; 2.1. Introduction; 2.2. Column, pH, and Solvent Screening; 2.2.1. Resolution: Goal of Separation; 2.2.2. Screening: Systematic Approach to Seeking Selectivity; 2.2.3. Screening Instrumentation and Controlling Software; 2.3. Gradient and Temperature Optimization; 2.4. Orthogonal Screening; 2.4.1. Method Orthogonality; 2.4.2. Selection of Orthogonal Methods; 2.4.3. Impurity Orthogonal Screening; 2.5. High-Efficiency Separation; 2.6. Conclusions; References 3. Rapid Analysis of Drug-Related Substances using Desorption Electrospray Ionization and Direct Analysis in Real Time Ionization Mass Spectrometry; 3.1. Introduction; 3.2. Ionization Apparatus, Mechanisms, and General Performance; 3.2.1. Desorption Electrospray Ionization (DESI); 3.2.2. Direct Analysis in Real Time (DART); 3.3. Drug Analysis in Biological Matrices using DESI and DART; 3.3.1. DESI Application; 3.3.2. DART Application; 3.4. High-Throughput Analysis; 3.5. Chemical Imaging and Profiling; 3.6. Future Perspectives; References; 4. Orbitrap High-Resolution Applications 4.1. Historical Anecdote; 4.2. General Description of Orbitrap Operating Principles; 4.3. The Orbitrap is a "Fourier Transform" Device; 4.4. Performing Experiments in Trapping Devices; 4.4.1. "Raw" HPLC Data Look Like Infusion Data; 4.4.2. How Much Mass Resolution Should Be Used During HPLC; 4.5. Determining Elemental Compositions of "Unknowns" Using an Orbitrap; 4.6. Orbitrap Figures of Merit in Mass Measurement; 4.6.1. Accuracy; 4.6.2. Precision; 4.6.3. Discussion; 4.7. HPLC Orbitrap MS: Accurate Mass Demonstration and Differentiation of Small Molecule Formulas Very Proximate in Mass/Charge Ratio Space |
| Record Nr. | UNINA-9910810569103321 |
| Hoboken : , : Wiley, , 2011 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
